Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Cabaletta Bio – Company Overview
Mission:
Harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients.
Vision:
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases.
Values:
- Prioritize the patient
- Listen to the data
- Serve the team
- Improve every day
- Pursue excellence and persevere
- Be authentic, vulnerable & courageous
- Embrace differences, demand equity & inspire trust
- Do the right thing
get REAL Initiative
Reflection
Monthly company-wide meetings & small group discussion
Education
Company resource library on initiatives and ways to engage with the Philadelphia community
Action
Leadership
